<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ru">
	<id>https://wiki.mininuniver.ru/index.php?action=history&amp;feed=atom&amp;title=~Delete_857</id>
	<title>~Delete 857 - История изменений</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.mininuniver.ru/index.php?action=history&amp;feed=atom&amp;title=~Delete_857"/>
	<link rel="alternate" type="text/html" href="https://wiki.mininuniver.ru/index.php?title=~Delete_857&amp;action=history"/>
	<updated>2026-06-24T09:22:19Z</updated>
	<subtitle>История изменений этой страницы в вики</subtitle>
	<generator>MediaWiki 1.32.0</generator>
	<entry>
		<id>https://wiki.mininuniver.ru/index.php?title=~Delete_857&amp;diff=376104&amp;oldid=prev</id>
		<title>Moderator: Moderator переименовал страницу A New Class of Mammalian Concentrate on of Rapamycin Inhibitors,Rapamycin, Romidepsin, Sorafenib в ~Delete 857: Spam</title>
		<link rel="alternate" type="text/html" href="https://wiki.mininuniver.ru/index.php?title=~Delete_857&amp;diff=376104&amp;oldid=prev"/>
		<updated>2025-12-18T01:54:53Z</updated>

		<summary type="html">&lt;p&gt;Moderator переименовал страницу &lt;a href=&quot;/index.php/A_New_Class_of_Mammalian_Concentrate_on_of_Rapamycin_Inhibitors,Rapamycin,_Romidepsin,_Sorafenib&quot; class=&quot;mw-redirect&quot; title=&quot;A New Class of Mammalian Concentrate on of Rapamycin Inhibitors,Rapamycin, Romidepsin, Sorafenib&quot;&gt;A New Class of Mammalian Concentrate on of Rapamycin Inhibitors,Rapamycin, Romidepsin, Sorafenib&lt;/a&gt; в &lt;a href=&quot;/index.php/~Delete_857&quot; title=&quot;~Delete 857&quot;&gt;~Delete 857&lt;/a&gt;: Spam&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;ru&quot;&gt;
				&lt;td colspan=&quot;1&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;← Предыдущая&lt;/td&gt;
				&lt;td colspan=&quot;1&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;Версия 01:54, 18 декабря 2025&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-notice&quot; lang=&quot;ru&quot;&gt;&lt;div class=&quot;mw-diff-empty&quot;&gt;(нет различий)&lt;/div&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</summary>
		<author><name>Moderator</name></author>
		
	</entry>
	<entry>
		<id>https://wiki.mininuniver.ru/index.php?title=~Delete_857&amp;diff=376103&amp;oldid=prev</id>
		<title>Moderator: Spam cleanup</title>
		<link rel="alternate" type="text/html" href="https://wiki.mininuniver.ru/index.php?title=~Delete_857&amp;diff=376103&amp;oldid=prev"/>
		<updated>2025-12-18T01:54:52Z</updated>

		<summary type="html">&lt;p&gt;Spam cleanup&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;ru&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;← Предыдущая&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;Версия 01:54, 18 декабря 2025&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot; &gt;Строка 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Строка 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Several such brokers have long gone into medical trials, for instance, OSI-027, AZD-8055 and INK-128.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;Content removed&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Several preclinical research have proposed much much more potent antineoplastic results of these kinds of inhibitors when when compared to rapamycin or other rapalogs. For instance, current work has demonstrated that the PP242 and OSI-027 twin TORC1/TORC2 inhibitors, the two of which act as allosteric catalytic inhibitors of the mTOR kinase, exhibit potent antileukemic effects in vitro and/or in vivo. These functions have shown outstanding exercise of these kinds of agents in the remedy of refractory Ph+ leukemias, like cells expressing the T315I mutation which is resistant to all diverse kinase inhibitors approved for the treatment of CML as nicely as in AML. Similarly, there is proof for strong inhibitory consequences of dual TORC1/TORC2 inhibitors on multiple myeloma cells, lymphoma, breast cancer cells, lung most cancers and other solid tumor types.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Focusing on the mTOR pathway for the therapy of malignancies is a rapidly progressing and evolving study spot with key implications in healthcare oncology. Numerous scientific trials with the Ã¯Â¬Ârst generation of mTOR inhibitors have offered proof of basic principle for the usefulness and clinical relevance of pharmacological inhibition of mTOR. In some circumstances, such as in the situation of renal carcinoma, these efforts have made excellent medical outcomes and even Food and drug administration approvals for the use of this sort of brokers. There is far more enthusiasm about the potential influence of 2nd-era, twin TORC1/TORC2, inhibitors. Efforts to identify predictive molecular and/or biochemical biomarkers of susceptibility to the two Ã¯Â¬Ârst and next era mTOR inhibitors and deÃ¯Â¬Âne tumor traits correlating with drug resistance may possibly let a far more optimum exploitation of the entire possible of this kind of agents in the near future.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;We has set up extended-term and stable associations with much more than 10,000 customers from pharmaceutical and biotech organizations, universities and research establishments. We have substantial high quality inhibitors like Celecoxib, Gemcitabine, Docetaxel &amp;amp; more. We have headquarters in the two United States and Europe, and also has 38 distributors globally. We provide right away shipping in North The united states and Europe.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;References&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Caron E, et al. Mol Syst Biol 2010 6: 453.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Richard DJ, et al. Curr Opin Drug Discov Devel 2010 13: 428-440.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Vu C, et al. Clin Cancer Res 2010 sixteen: 5374-5380.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Efeyan A, et al. Curr Opin Mobile Biol 2010 22: 169-176.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Albert S, et al. Expert Opin Investig Medicines 2010 19: 919-930.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Janes MR, et al. Nat Med 2010 sixteen: 205-213.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Altman JK, et al. Clin Most cancers Res 2011 17: 4378-4388.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Garcia-Martinez JM, et al. Br J Cancer 2011 104: 1116-1125.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Falcon BL, et al. Most cancers Res 2011 71: 1573-1583.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Associated Posts&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Clinical Expertise of Rapamycin Inhibitors in the Remedy of Hematological Malignancies&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Posts Relevant to A New Course of Mammalian Concentrate on of Rapamycin Inhibitors&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Scientific Knowledge of Rapamycin Inhibitors in the Treatment of Hematological Malignancies&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;The PI3K/AKT/mammalian goal of rapamycin (mTOR) pathway is often deregulated in a lot of malignancies, generating it an important focus on for drug development. [http://ensynefo.com/blogs/411952/589184/major-diseases-of-aging-unified Major Diseases of Aging Unified by a Global Theory - Easy, Simple Practices Let You Live Longer], [http://community.babycenter.com/journal/nurseink29/10175944/essesntial_aminos_plus_carbs_increase_protein_synthesis_after_training You Can Learn a Lot From a Monkey], [http://ebook-music-software.com/blogs/viewstory/536438 Essesntial Aminos Plus Carbs Increase Protein Synthesis After Training]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Moderator</name></author>
		
	</entry>
	<entry>
		<id>https://wiki.mininuniver.ru/index.php?title=~Delete_857&amp;diff=132949&amp;oldid=prev</id>
		<title>Activerabbit55: Новая: Several such brokers have long gone into medical trials, for instance, OSI-027, AZD-8055 and INK-128. Several preclinical research have proposed much much more potent antineoplastic resu...</title>
		<link rel="alternate" type="text/html" href="https://wiki.mininuniver.ru/index.php?title=~Delete_857&amp;diff=132949&amp;oldid=prev"/>
		<updated>2013-04-29T11:20:56Z</updated>

		<summary type="html">&lt;p&gt;Новая: Several such brokers have long gone into medical trials, for instance, OSI-027, AZD-8055 and INK-128. Several preclinical research have proposed much much more potent antineoplastic resu...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Новая страница&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Several such brokers have long gone into medical trials, for instance, OSI-027, AZD-8055 and INK-128.&lt;br /&gt;
Several preclinical research have proposed much much more potent antineoplastic results of these kinds of inhibitors when when compared to rapamycin or other rapalogs. For instance, current work has demonstrated that the PP242 and OSI-027 twin TORC1/TORC2 inhibitors, the two of which act as allosteric catalytic inhibitors of the mTOR kinase, exhibit potent antileukemic effects in vitro and/or in vivo. These functions have shown outstanding exercise of these kinds of agents in the remedy of refractory Ph+ leukemias, like cells expressing the T315I mutation which is resistant to all diverse kinase inhibitors approved for the treatment of CML as nicely as in AML. Similarly, there is proof for strong inhibitory consequences of dual TORC1/TORC2 inhibitors on multiple myeloma cells, lymphoma, breast cancer cells, lung most cancers and other solid tumor types.&lt;br /&gt;
Focusing on the mTOR pathway for the therapy of malignancies is a rapidly progressing and evolving study spot with key implications in healthcare oncology. Numerous scientific trials with the Ã¯Â¬Ârst generation of mTOR inhibitors have offered proof of basic principle for the usefulness and clinical relevance of pharmacological inhibition of mTOR. In some circumstances, such as in the situation of renal carcinoma, these efforts have made excellent medical outcomes and even Food and drug administration approvals for the use of this sort of brokers. There is far more enthusiasm about the potential influence of 2nd-era, twin TORC1/TORC2, inhibitors. Efforts to identify predictive molecular and/or biochemical biomarkers of susceptibility to the two Ã¯Â¬Ârst and next era mTOR inhibitors and deÃ¯Â¬Âne tumor traits correlating with drug resistance may possibly let a far more optimum exploitation of the entire possible of this kind of agents in the near future.&lt;br /&gt;
We has set up extended-term and stable associations with much more than 10,000 customers from pharmaceutical and biotech organizations, universities and research establishments. We have substantial high quality inhibitors like Celecoxib, Gemcitabine, Docetaxel &amp;amp; more. We have headquarters in the two United States and Europe, and also has 38 distributors globally. We provide right away shipping in North The united states and Europe.&lt;br /&gt;
References&lt;br /&gt;
Caron E, et al. Mol Syst Biol 2010 6: 453.&lt;br /&gt;
Richard DJ, et al. Curr Opin Drug Discov Devel 2010 13: 428-440.&lt;br /&gt;
Vu C, et al. Clin Cancer Res 2010 sixteen: 5374-5380.&lt;br /&gt;
Efeyan A, et al. Curr Opin Mobile Biol 2010 22: 169-176.&lt;br /&gt;
Albert S, et al. Expert Opin Investig Medicines 2010 19: 919-930.&lt;br /&gt;
Janes MR, et al. Nat Med 2010 sixteen: 205-213.&lt;br /&gt;
Altman JK, et al. Clin Most cancers Res 2011 17: 4378-4388.&lt;br /&gt;
Garcia-Martinez JM, et al. Br J Cancer 2011 104: 1116-1125.&lt;br /&gt;
Falcon BL, et al. Most cancers Res 2011 71: 1573-1583.&lt;br /&gt;
Associated Posts&lt;br /&gt;
Clinical Expertise of Rapamycin Inhibitors in the Remedy of Hematological Malignancies&lt;br /&gt;
Posts Relevant to A New Course of Mammalian Concentrate on of Rapamycin Inhibitors&lt;br /&gt;
Scientific Knowledge of Rapamycin Inhibitors in the Treatment of Hematological Malignancies&lt;br /&gt;
The PI3K/AKT/mammalian goal of rapamycin (mTOR) pathway is often deregulated in a lot of malignancies, generating it an important focus on for drug development. [http://ensynefo.com/blogs/411952/589184/major-diseases-of-aging-unified Major Diseases of Aging Unified by a Global Theory - Easy, Simple Practices Let You Live Longer], [http://community.babycenter.com/journal/nurseink29/10175944/essesntial_aminos_plus_carbs_increase_protein_synthesis_after_training You Can Learn a Lot From a Monkey], [http://ebook-music-software.com/blogs/viewstory/536438 Essesntial Aminos Plus Carbs Increase Protein Synthesis After Training]&lt;/div&gt;</summary>
		<author><name>Activerabbit55</name></author>
		
	</entry>
</feed>